Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8245626 | International Journal of Radiation Oncology*Biology*Physics | 2006 | 9 Pages |
Abstract
Conclusions: This intensive treatment regimen of concurrent docetaxel/concomitant boost radiation and surgery after induction chemotherapy in poor prognosis patients yields good local regional control and survival. Docetaxel/CB chemoradiotherapy represents an aggressive alternative regimen to platinum-based chemoradiotherapy or surgery in patients who have a poor response to induction chemotherapy.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Roy B. M.D., Ph.D., Marshall R. M.D., Charles M. M.D., Anand M.D., Christopher M.D., Laura M.D., Lori J. M.D., Rosemary R.N., MaryAnn R.N., Sara B.S., Dan B.S., Paul M. M.D., Ph.D., Robert I. M.D.,